Makers Laboratories Ltd Stock Price Today (NSE: MAKERSL)
Fundamental Score
Makers Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Makers Laboratories Ltd share price today is ₹148.70, up +0.41% on NSE/BSE as of 17 June 2026. Makers Laboratories Ltd (MAKERSL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹70.98 (Cr). The 52-week high for MAKERSL share price is ₹186.70 and the 52-week low is ₹109.00. The company has a Return on Equity (ROE) of 3.36% and a debt-to-equity ratio of 0.11.
Makers Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Makers Laboratories Ltd share price chart: 17.05% return over the past month. 52-week high ₹186.70, 52-week low ₹109.00.
Makers Laboratories Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹161.45 | ₹164.50 | ₹158.00 | ₹158.45 | 3.68K (Cr) | |
| ₹163.30 | ₹178.00 | ₹160.25 | ₹162.30 | 17.33K (Cr) | |
| ₹168.05 | ₹174.70 | ₹163.20 | ₹163.75 | 8.72K (Cr) | |
| ₹172.35 | ₹178.00 | ₹165.70 | ₹166.80 | 15.57K (Cr) | |
| ₹164.90 | ₹172.95 | ₹160.10 | ₹165.55 | 13.81K (Cr) | |
| ₹164.25 | ₹168.75 | ₹158.60 | ₹161.30 | 8.16K (Cr) | |
| ₹161.00 | ₹167.00 | ₹158.00 | ₹164.25 | 36.29K (Cr) | |
| ₹179.95 | ₹179.95 | ₹155.10 | ₹161.00 | 52.77K (Cr) | |
| ₹158.70 | ₹186.70 | ₹158.00 | ₹176.45 | 1.35L (Cr) | |
| ₹161.25 | ₹165.00 | ₹154.00 | ₹155.60 | 5.05K (Cr) |
Makers Laboratories Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹163.30 | ₹178.00 | ₹158.00 | ₹158.45 | -2.97% | |
| ₹140.35 | ₹186.70 | ₹140.35 | ₹163.75 | +16.67% | |
| ₹130.65 | ₹168.00 | ₹130.65 | ₹141.05 | +7.96% | |
| ₹142.90 | ₹171.00 | ₹133.60 | ₹135.20 | -5.39% | |
| ₹128.00 | ₹164.70 | ₹116.05 | ₹146.30 | +14.30% | |
| ₹123.45 | ₹129.00 | ₹112.10 | ₹119.50 | -3.20% | |
| ₹125.00 | ₹125.00 | ₹109.00 | ₹118.15 | -5.48% | |
| ₹122.00 | ₹139.15 | ₹117.15 | ₹120.20 | -1.48% | |
| ₹130.00 | ₹144.90 | ₹119.00 | ₹121.85 | -6.27% | |
| ₹147.60 | ₹151.90 | ₹128.50 | ₹130.00 | -11.92% | |
| ₹152.00 | ₹163.80 | ₹144.50 | ₹148.95 | -2.01% | |
| ₹150.00 | ₹168.00 | ₹144.00 | ₹151.95 | +1.30% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Makers Laboratories Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Makers Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of MAKERSL across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Revenue Growth (15.56%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.11)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (8.90x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (61.27%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (3.36%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (4.25%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-101.37%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Negative Free Cash Flow (₹-6.73 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.39%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Makers Laboratories Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Makers Laboratories Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Makers Laboratories LtdMakers Laborato...Selected✓ MAKERSL • 506919 | 18.8/100 | ₹148.70₹149 | ₹70.98₹70.98 | — — | 3.36%Poor 3.36% Poor | 4.25%Poor 4.25% Poor | 0.11Excellent 0.1 Excellent | — — | — — | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Makers Laboratories Ltd Dividend History
Annual cash dividends paid by MAKERSL — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2024 | ₹0.63 Cr |
| FY 2023 | ₹0.63 Cr |
| FY 2022 | ₹0.63 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Makers Laboratories Ltd Quarterly Performance
Latest quarterly metrics for MAKERSL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
15.56%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-101.37%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Makers Laboratories Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for MAKERSL — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Makers Laboratories Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Makers Laboratories Ltd (MAKERSL) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Makers Laboratories Ltd
About MAKERSL (Makers Laboratories Ltd)
Makers Laboratories Ltd is a dynamic pharmaceutical entity deeply rooted in the Indian healthcare landscape, committed to developing, manufacturing, and distributing a diverse port...folio of pharmaceutical products. Operating with a dual focus, the company strategically divides its operations into two synergistic segments: pharmaceutical formulations and chemical manufacturing. This integrated approach enables Makers Laboratories to maintain stringent quality control throughout the entire production process, from the sourcing of raw materials to the final packaged product, ensuring patient safety and therapeutic efficacy. The company relentlessly pursues innovation, investing in research and development to create effective and affordable healthcare solutions tailored to the specific needs of the Indian population. The core of Makers Laboratories' success lies in its comprehensive range of therapeutic products, designed to address a broad spectrum of health concerns. The company offers solutions for common ailments and chronic conditions, including treatments for digestive disorders, infections, allergies, respiratory issues, and metabolic imbalances. Specifically, their product line features medications targeting acid reflux, parasitic worms, allergic reactions, asthma, bacterial infections, diabetes, diarrhea, nausea, fungal infections, hypertension, inflammation, pain, muscle spasms, malaria, and thyroid imbalances. This wide-ranging portfolio demonstrates Makers Laboratories' dedication to providing accessible and reliable healthcare solutions to meet the diverse medical needs of the Indian populace. Driven by a commitment to ethical business practices and unwavering quality standards, Makers Laboratories strives to enhance the well-being of individuals and communities. The company actively seeks to expand its reach and impact by leveraging its manufacturing capabilities, distribution networks, and strategic partnerships. With a strong emphasis on customer satisfaction and continuous improvement, Makers Laboratories remains dedicated to strengthening its position as a trusted provider of high-quality pharmaceutical products in the Indian market. They aspire to be a vital contributor to a healthier and more prosperous India.
Company Details
Key Leadership
Corporate Events
Latest News
MAKERSL Share Price: Frequently Asked Questions
What is the current share price of Makers Laboratories Ltd?
Makers Laboratories Ltd (MAKERSL) trades at ₹148.70 on NSE and BSE. Market cap ₹70.98 (Cr). Educational data only.
What is the P/E ratio of Makers Laboratories Ltd?
Makers Laboratories Ltd has a P/E of N/Ax vs industry average 31.77x.
What is the Bull Run score for Makers Laboratories Ltd?
Makers Laboratories Ltd has a Bull Run score of 18.8/100 based on 25+ financial parameters.
Does Makers Laboratories Ltd pay dividends?
Makers Laboratories Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Makers Laboratories Ltd?
Makers Laboratories Ltd has ROE of 3.36%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Makers Laboratories Ltd?
Makers Laboratories Ltd has debt-to-equity of 0.11.
Is Makers Laboratories Ltd a good investment?
Bull Run gives Makers Laboratories Ltd a score of 18.8/100. This is not investment advice — consult a SEBI-registered advisor.